- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (16)
21 result(s) found for: Glia.
Displaying page 1 of 2.
| EudraCT Number: 2016-003529-41 | Sponsor Protocol Number: ABR58805 | Start Date*: 2017-02-22 |
| Sponsor Name:University Medical Center Utrecht | ||
| Full Title: CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia | ||
| Medical condition: Schizophrenia patients | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-005573-21 | Sponsor Protocol Number: GLIOMARK1 | Start Date*: 2016-04-26 | |||||||||||
| Sponsor Name:pro-ACTINA S.A. | |||||||||||||
| Full Title: Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis | |||||||||||||
| Medical condition: Patients with high grade brain tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-012582-64 | Sponsor Protocol Number: 337/09 | Start Date*: 2009-07-29 | |||||||||||
| Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
| Full Title: Treatment with bevacizumab and irinotecan in patients with recurrent or refractory high grade glioma after conventional treatment. | |||||||||||||
| Medical condition: high grade glioma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004974-27 | Sponsor Protocol Number: BP28015 | Start Date*: 2012-03-26 | |||||||||||
| Sponsor Name:University Medical Center Groningen | |||||||||||||
| Full Title: 89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab | |||||||||||||
| Medical condition: Recurrent malignant glioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-018447-34 | Sponsor Protocol Number: 06MH34 | Start Date*: 2011-09-22 | |||||||||||
| Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | |||||||||||||
| Full Title: Investigation of dendritic cell vaccine immunotherapy in paediatric high grade glioma | |||||||||||||
| Medical condition: Paediatric High grade glioma, excluding brain stem gliomas | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-015036-15 | Sponsor Protocol Number: AVIRMA | Start Date*: 2010-01-21 | |||||||||||
| Sponsor Name:Medizinische Universität Innsbruck - Universitätsklinik für Neurologie | |||||||||||||
| Full Title: Avastin / Irinotecan in patients with recurrent or progressive malignant glioma An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging techni... | |||||||||||||
| Medical condition: First or second tumour recrurrence/progression of a histological confirmed supratentorial malignant glioma WHO Grade III-IV | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-005644-24 | Sponsor Protocol Number: BERTES-01 | Start Date*: 2007-11-27 | |||||||||||||||||||||
| Sponsor Name:AMC-UvA | |||||||||||||||||||||||
| Full Title: Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients | |||||||||||||||||||||||
| Medical condition: Primary Glioblastoma Multiforme | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2008-007295-14 | Sponsor Protocol Number: 26081-22086 | Start Date*: 2010-11-17 | ||||||||||||||||||||||||||
| Sponsor Name:European Organization for Research and Treatment of Cancer (EORTC) | ||||||||||||||||||||||||||||
| Full Title: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. | ||||||||||||||||||||||||||||
| Medical condition: Newly Diagnosed Anaplastic Glioma with Chromosomal co-deletions of 1p and 19q | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2022-000636-40 | Sponsor Protocol Number: PNOC022 | Start Date*: 2022-10-20 | |||||||||||||||||||||
| Sponsor Name:Pacific Pediatric Neuro-Oncology Consortium (PNOC) | |||||||||||||||||||||||
| Full Title: PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initi... | |||||||||||||||||||||||
| Medical condition: Diffuse Midline Gliomas, H3K27M mutant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2006-003193-10 | Sponsor Protocol Number: CDKO-125a-002 | Start Date*: 2009-02-24 | ||||||||||||||||
| Sponsor Name:Nerviano Medical Sciences S.r.l. | ||||||||||||||||||
| Full Title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma | ||||||||||||||||||
| Medical condition: Phase I Part: Recurrent Malignant Glioma Phase II Part: Recurrent Glioblastoma Multiforme | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) ES (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-001119-30 | Sponsor Protocol Number: 2B3-101-CR-001 | Start Date*: 2011-06-22 | |||||||||||||||||||||||||||||||
| Sponsor Name:to-BBB technologies B.V. | |||||||||||||||||||||||||||||||||
| Full Title: An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma. | |||||||||||||||||||||||||||||||||
| Medical condition: Solid tumors and brain metastases or recurrent malignant glioma, HER2-positive adenocarcinoma of the breast with brain metastases | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) BE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-019348-37 | Sponsor Protocol Number: CLDE225X2104 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway | ||||||||||||||||||||||||||||||||||||||
| Medical condition: pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway (rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-004187-56 | Sponsor Protocol Number: HIT-HGG-2013 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Restarted) AT (Ongoing) NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-003005-10 | Sponsor Protocol Number: IGR2012/1883 | Start Date*: 2013-06-06 | |||||||||||||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
| Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA | |||||||||||||||||||||||
| Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-002762-44 | Sponsor Protocol Number: RG-16-040 | Start Date*: 2018-05-01 | ||||||||||||||||||||||||||
| Sponsor Name:University of Birmingham | ||||||||||||||||||||||||||||
| Full Title: A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults | ||||||||||||||||||||||||||||
| Medical condition: Relpased/refractory paeditaric cancers: Leukaemias Sarcoma Neuroblastoma High grade glioma (brain cancers) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-000854-85 | Sponsor Protocol Number: CA045-020 | Start Date*: 2021-04-19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Recurrent or Refractory pediatric cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended) Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-002931-27 | Sponsor Protocol Number: I3Y-MC-JPCS | Start Date*: 2020-10-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Rela... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Pediatric and Young Adult Patients Relapsed/Refractory Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-022189-28 | Sponsor Protocol Number: BO25041 | Start Date*: 2011-08-12 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE II OPEN-LABEL, RANDOMIZED, MULTI- CENTRE COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR ... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Newly diagnosed high-grade glioma | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) AT (Completed) CZ (Completed) DE (Completed) GB (Completed) SE (Completed) HU (Completed) FR (Completed) ES (Completed) DK (Completed) FI (Prematurely Ended) NL (Completed) IT (Completed) PL (Completed) Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
